Patients with KRAS-mutant NSCLC had a poor prognosis [33], and KRASG12C mutation with a poorer prognosis compared with other KRAS mutations [34] accounted for 42% of KRAS-mutant lung adenocarcinoma [35]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.